ARVN (Arvinas) 3-Year Book Growth Rate : -18.00% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Arvinas 3-Year Book Growth Rate?

Arvinas's Book Value per Share for the quarter that ended in Dec. 2024 was $8.16.

During the past 12 months, Arvinas's average Book Value per Share Growth Rate was -15.90% per year. During the past 3 years, the average Book Value per Share Growth Rate was -18.00% per year. During the past 5 years, the average Book Value per Share Growth Rate was 1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 9 years, the highest 3-Year average Book Value per Share Growth Rate of Arvinas was 50.10% per year. The lowest was -18.00% per year. And the median was 5.90% per year.

Competitive Comparison of Arvinas's 3-Year Book Growth Rate

For the Biotechnology subindustry, Arvinas's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arvinas's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arvinas's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Arvinas's 3-Year Book Growth Rate falls into.

Arvinas 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Arvinas (NAS:ARVN) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Arvinas 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Arvinas's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Arvinas Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arvinas Inc (NAS:ARVN) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511

Website

https://www.arvinas.com

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Executives

David K Loomis	officer: Chief Accounting Officer	C/O 5 SCIENCE PARK, 385 WINCHESTER AVENUE, NEW HAVEN CT 06511
Ian Taylor	officer: Senior Vice President, Biology	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 0651
John G Houston	director, officer: President and CEO	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sean A Cassidy	officer: Chief Financial Officer	322 EAST MAIN STREET, BRANFORD CT 06405
Ronald Peck	officer: Chief Medical Officer	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Sunil Agarwal	director	60 LEVERONI COURT, NOVATO CA 94949
Everett Cunningham	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
John D Young	director	C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Briggs Morrison	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Liam Ratcliffe	director, 10 percent owner	C/O ACCESS INDUSTRIES, INC, 40 WEST 57TH ST, 28TH FLOOR, NEW YORK NY 10019
Timothy M Shannon	director	C/O CURAGEN CORP, 555LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Bradley Albert Margus	director	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Kennedy Edward Moore Jr.	director	C/O ARVINAS, INC. 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Wendy L Dixon	director
Linda Bain	director	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139